MCL Literature Feed

Ibrutinib plus venetoclax shows high efficacy (83% CR) and deep MRD negativity with good tolerability in Japanese patients with relapsed/refractory MCL, supporting its use in this population.

This Japanese post-marketing surveillance study confirms the real-world efficacy (59.9% ORR) and safety of ibrutinib in heavily pre-treated, elderly patients with relapsed/refractory MCL, supporting its routine use.

This 2024 review of 80 FDA-approved kinase inhibitors highlights pirtobrutinib's recent approval for relapsed/refractory MCL, contextualizing its properties within the broader landscape of targeted therapies.

This Phase 1 study establishes the safety and recommended dose of a quadruplet regimen combining chemoimmunotherapy (BR) with dual targeted agents (ibrutinib, venetoclax) for relapsed/refractory MCL.

This preclinical study identifies the protease SENP3 as a novel driver of MCL proliferation via the Wnt10a signaling pathway, presenting SENP3 as a potential new therapeutic target.

Optical genomic mapping (OGM) identifies rare CCND1 rearrangements, securing an MCL diagnosis in atypical CD5-negative, non-nodal cases that mimic other indolent B-cell lymphomas.

This retrospective study of 134 patients demonstrates that adding a BTK inhibitor to chemotherapy improves efficacy and prolongs progression-free survival in relapsed/refractory MCL.

Preclinically, chlorambucil and ibrutinib show synergistic apoptosis in an MCL cell line, suggesting a novel chemo-BTKi combination strategy potentially mediated by inhibiting the AKT signaling pathway.

A novel BRAF N581S mutation was identified in mantle cell lymphoma, expanding the known genomic landscape and suggesting a potential new therapeutic target for this rare patient subset.

This case report documents the first complete response of frontline CNS-involved MCL to single-agent acalabrutinib, suggesting a potential chemotherapy-free, CNS-penetrant option for this high-risk population.

An MRD-driven, finite-duration venetoclax-lenalidomide-rituximab regimen is effective in relapsed/refractory MCL, even post-BTKi, allowing nearly half of patients to stop therapy and maintain durable molecular remissions.

The deubiquitinase USP35 stabilizes CXCR3 protein expression in MCL cells, promoting oncogenic signaling via JAK/STAT and c-Myc, identifying the USP35-CXCR3 axis as a novel therapeutic target.

This study developed and validated a new lymphoma-specific patient-reported outcome measure using the EORTC Item Library, providing a crucial tool for assessing MCL symptoms in clinical trials.

This 15-year real-world study benchmarks MCL survival outcomes, reflecting evolving treatment eras and providing crucial prognostic data from routine clinical practice.

Upregulation of the mTOR pathway drives acquired resistance to PRMT5 inhibitors in preclinical MCL models; combining with an mTOR inhibitor like temsirolimus overcomes this resistance and improves survival.

Pirtobrutinib, a non-covalent BTKi, gained FDA accelerated approval for MCL after prior BTKi failure, offering a 50% overall response rate for this high-unmet-need population.

This review summarizes the rare presentation of mantle cell lymphoma in the lacrimal sac, highlighting the unique diagnostic and multidisciplinary therapeutic challenges posed by this specific anatomical site.

Final overall survival data from a phase 2 trial confirm durable responses to acalabrutinib monotherapy in relapsed/refractory MCL, including in patients with poor prognostic features.

This pathology workshop report clarifies the differential diagnosis of aggressive B-cell lymphomas, including pleomorphic MCL, by applying updated WHO-HAEM5 and ICC 2022 classifications for improved diagnostic accuracy.

Radiation therapy is a feasible bridging strategy to control disease in relapsed/refractory MCL patients awaiting CAR-T infusion, potentially improving eligibility and outcomes for those with bulky disease.

This review analyzes the regulatory challenges and decision-making complexities for ibrutinib in MCL, stemming from inconsistent results across different pivotal clinical trials.

This paper proposes using the estimand framework to standardize definitions of Duration of Response (DOR) and Time to Response (TTR), using an MCL case study to improve trial endpoint clarity.

This review summarizes the evolution of MCL treatment, focusing on BTK inhibitor efficacy, toxicity, and their role in enabling personalized therapeutic strategies based on patient and disease factors.

Pirtobrutinib, the first approved non-covalent BTKi, offers a crucial new therapy for relapsed/refractory MCL by overcoming resistance mechanisms, including C481 mutations, from prior covalent BTK inhibitors.

This indirect comparison of ZUMA-2 (brexucabtagene autoleucel) and SCHOLAR-2 (standard of care) demonstrates a substantial overall survival benefit for CAR-T therapy in relapsed/refractory MCL after BTKi failure.

The British Society for Haematology provides updated, evidence-based guidelines on MCL diagnosis, risk stratification, and treatment algorithms, standardizing care for UK patients.

This commentary highlights the new British Society for Haematology guidelines, offering updated, comprehensive recommendations for MCL diagnosis and management, including guidance for difficult-to-treat clinical scenarios.

Combining the MCL35 gene signature with s-MIPI and blastoid cytology powerfully risk-stratifies older, frontline MCL patients receiving bendamustine-rituximab, identifying a dismal prognosis subgroup.

This review synthesizes MCL's genomic heterogeneity with the evolving therapeutic landscape, focusing on novel agents like BTKi and CAR-T and strategies for overcoming resistance in relapsed/refractory disease.

Pirtobrutinib, a non-covalent BTKi, shows a 52% overall response rate in relapsed/refractory MCL, including in patients previously treated with covalent BTKi, offering a new therapeutic option.